1. Diagnosis and Management of T2-High Asthma
- Author
-
Max A. Seibold, Michael C. Peters, and Andrea M. Coverstone
- Subjects
Inflammation ,Nitric Oxide ,Immunoglobulin E ,Pathogenesis ,immune system diseases ,Eosinophilia ,Humans ,Immunology and Allergy ,Medicine ,Monoclonal antibody therapy ,Asthma ,Interleukin-13 ,biology ,business.industry ,Sputum ,respiratory system ,medicine.disease ,respiratory tract diseases ,Eosinophils ,Immunology ,Exhaled nitric oxide ,biology.protein ,Interleukin-4 ,Interleukin-5 ,medicine.symptom ,Airway ,business ,Biomarkers - Abstract
Type 2 (T2) inflammation plays a key role in the pathogenesis of asthma. IL-4, IL-5, and IL-13, along with other inflammatory mediators, lead to increased cellular eosinophilic inflammation. It is likely that around half of all patients with asthma have evidence of T2-high inflammation. Sputum and blood eosinophils, exhaled nitric oxide, blood IgE levels, and airway gene expression markers are frequently used biomarkers of T2-high asthma. Individuals with T2-high asthma tend to have several features of increased asthma severity, including reduced lung function and increased rates of asthma exacerbations, and T2-high patients demonstrate distinct pathologic features including increased airway remodeling and alterations in airway mucus production. Several monoclonal antibodies are now available to treat individuals with T2-high asthma and these medications significantly reduce asthma exacerbation rates.
- Published
- 2020
- Full Text
- View/download PDF